Lichen sclerosus: an under-recognised vulval condition where treatment lowers cancer risk

Lichen sclerosus is a chronic inflammatory skin disease that most often affects the anogenital area, is frequently mistaken for thrush or irritation and left untreated for years, and — unlike most itchy skin complaints — carries a small but real risk of progressing to vulval cancer that treatment appears to reduce [s1][s2]. The core message of the evidence is unusual for a skin condition: consistent topical steroid treatment is not only for symptom relief but is associated with a lower risk of cancer [s2].

What the condition is

Lichen sclerosus produces white, thinned, sometimes fissured or scarred skin, typically with intense itch or soreness, and in the genital area it can distort the normal anatomy over time as scarring sets in. The European S3 guideline stresses that anyone with symptoms or signs suspicious of lichen sclerosus should be seen at least once by a physician with a special interest in the disease, precisely to avoid the diagnostic delay that lets scarring establish — early treatment may even cure the disease in some patients and reduce or prevent scarring [s1]. In most cases the diagnosis is made clinically, with biopsy reserved for specific circumstances rather than performed routinely [s1].

The under-recognition is the first problem. Because the symptoms overlap with far more common complaints, women can spend years being treated for recurrent infections before the actual condition is named — the same pattern of diagnostic delay that dogs other gynaecological conditions, where a treatable disease hides behind vaguer labels.

The treatment, and what it is for

The guideline is clear that the gold standard of treatment remains potent to very potent topical steroids, applied to the affected skin [s1]. This is where lichen sclerosus differs from an ordinary rash: the goal is not simply to settle a flare but to bring the skin back to normal colour and texture and keep it there, because the disease is a relapsing, long-term condition rather than a one-off [s1]. In boys and men, the guideline notes, mild and moderate anogenital disease may be cured by circumcision, and certain triggers should be avoided [s1].

Because the treatment involves potent topical corticosteroids and the disease bears on a cancer risk and can alter anatomy, the choice of steroid potency, how it is applied and how long treatment continues are decisions for a clinician — this article describes the evidence, not a regimen to follow.

The cancer-risk evidence

The most informative study of long-term management is a prospective cohort of 507 women with biopsy-proved vulvar lichen sclerosus, followed in specialist practice for a mean of 4.7 years (range 2.0 to 6.8) [s2]. Their mean age at presentation was 55.4 years, and they had lived with symptoms for a mean of 5.0 years before the study began — itself a marker of how long the condition goes under-treated [s2]. Remission was induced with a potent steroid, then maintained with a preventive regimen titrated to keep the skin looking and feeling normal [s2].

The split in outcomes fell along adherence. Of the 507 women, 357 (70.4%) followed the treatment instructions and were classed as compliant; 150 (29.6%) did not and were classed as partially compliant [s2]. During follow-up, biopsy-proved squamous cell carcinoma or vulvar intraepithelial neoplasia — the pre-cancerous change — occurred in none of the compliant patients, against 7 (4.7%) of the partially compliant [s2]. The compliant group also had better symptom control and less scarring, and the adverse effects of the topical steroids were minimal [s2].

How much this proves

This is a single-centre cohort, not a randomised trial, and the comparison is between women who did and did not keep up treatment — groups that may differ in other ways that also affect outcome, so the finding shows a strong association rather than proving cause [s2]. But the direction aligns with the biology and with why the guideline frames continuous control as the aim: chronic, uncontrolled inflammation and scarring are thought to be what drives the malignant risk, and keeping the skin normal is the thing treatment can plausibly change [s1][s2]. It is a rare instance where the case for sticking with an unglamorous maintenance treatment is not only comfort but cancer prevention.

What it means for a reader

The practical takeaways are that persistent vulval itch, soreness, whitening or splitting skin deserve a proper diagnosis rather than repeated infection treatments, and that if lichen sclerosus is diagnosed, it is a long-term condition in which continued treatment and follow-up matter more than a single course [s1][s2]. That places it alongside other vulvovaginal problems that are commonly undertreated. None of this is medical advice; diagnosis, steroid choice and monitoring belong to a clinician.

What to watch

Whether earlier diagnosis and better long-term follow-up narrow the gap the cohort exposed — the women who did worst were not those who lacked an effective treatment, but those whose condition was caught late or whose maintenance lapsed [s2].

Sources

• Evidence-based (S3) Guideline on (anogenital) Lichen sclerosus — Journal of the European Academy of Dermatology and Venereology, 2015-07-22
• Long-term Management of Adult Vulvar Lichen Sclerosus: A Prospective Cohort Study of 507 Women — JAMA Dermatology, 2015-06-12